Safety Profile and Patient Guidance for Elacestrant: Practical Considerations With Oral Elacestrant

EP: 1.When Stable Disease Progresses: ESR1 Mutations at the Point Of Progression In Juliana’s Case

EP: 2.Targeting Resistance: Liquid Biopsy and the Role of SERDs In ESR1-Mutated mBC

EP: 3.Oral SERDs In Focus: EMERALD Findings and Practical Considerations for Evidence-Based Treatment Selection

Now Viewing

EP: 4.Safety Profile and Patient Guidance for Elacestrant: Practical Considerations With Oral Elacestrant

Video content above is prompted by the following:

The discussion explores the treatment sequencing and considerations for patients with multiple targetable mutations in metastatic breast cancer. The panelists emphasize the importance of patient-specific factors when choosing subsequent therapies, considering aspects such as treatment tolerance, adverse effect profiles, and patient preferences. Marti-Smith suggests prioritizing therapies with better tolerability, such aselacestrant, which has a more manageable adverse effect profile compared with other targeted therapies.

The experts deliberate on the strategic approach to treating patients with concurrent mutations, such as estrogen receptor 1 and PI3 kinase mutations. They recommend considering the ease of medication management, patient quality of life, and potential future treatment options. The conversation highlights the complexity of treatment decisions in metastatic breast cancer, where balancing efficacy, adverse effects, and patient comfort becomes crucial in maintaining long-term treatment adherence and overall well-being.

The panel also discusses the considerations of metastatic sites in treatment selection, noting that while clinical trials have included patients with various metastatic locations, individual patient circumstances remain paramount. They emphasize a personalized approach that takes into account the extent of disease, patient performance status, and potential for response to different therapies. This nuanced discussion underscores the importance of a comprehensive, patient-centered approach in managing metastatic breast cancer.